LONGHORN VACCINES & DIAGNOSTICS
Longhorn Vaccines & Diagnostics is an Industry Leading Biotechnology Company. Longhorn Vaccines and Diagnostics LLC is a closely held, veteran-owned company. With an emphasis on innovation, the company has developed unique, groundbreaking products for the molecular testing market, and active and passive vaccination that meet critical unmet needs in both the Developed and Developing World.
LONGHORN VACCINES & DIAGNOSTICS
Industry:
Biotechnology Health Care
Address:
Bethesda, Maryland, United States
Country:
United States
Website Url:
http://www.lhnvd.com
Status:
Active
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible Google Analytics Google Tag Manager Content Delivery Network Global Site Tag Organization Schema COVID-19 Typekit Squarespace
Official Site Inspections
http://www.lhnvd.com
- Host name: 198.185.159.145
- IP address: 198.185.159.145
- Location: New York United States
- Latitude: 40.7157
- Longitude: -74
- Metro Code: 501
- Timezone: America/New_York
- Postal: 10013
More informations about "Longhorn Vaccines & Diagnostics"
Longhorn Vaccines & Diagnostics
Longhorn is developing novel, industry-changing solutions to better diagnose, prevent, and treat disease. We are a Veteran and family owned One Health company addressing human and …See details»
Who We Are | Longhorn Vaccines & Diagnostics
Longhorn Vaccines and Diagnostics, LLC is a veteran-owned, family-funded company, focused on molecular tool, assay and vaccine development. With an emphasis on innovation, our goal is to improve molecular diagnostics to serve …See details»
Leadership - Longhorn Vaccines & Diagnostics
Gerald W. Fischer, MD, is the Chairman and Chief Executive Officer of Longhorn and an internationally recognized leader in pediatric and infectious disease care and research. He received a B.A. from Lewis and Clark College in 1968 and …See details»
Longhorn Vaccines and Diagnostics Presents at World Vaccine
Apr 2, 2024 · LHNVD-110, a single peptide vaccine with multiple epitopes, generates neutralizing antibodies against highly infectious strains of influenza, demonstrating the potential for longer …See details»
Longhorn Vaccines and Diagnostics Provides Mid-Year Progress …
Jul 31, 2024 · Late-stage pre-clinical development progresses for LHNVD-302 anti-sepsis vaccine with extended half-life antibodiesSee details»
Longhorn Vaccines and Diagnostics to Present Data on …
Nov 7, 2024 · LHNVD-303 is a vaccine designed to prevent antibiotic resistant bacterial infections, and clear associated toxins, including those related to Mycobacterium tuberculosis, using a …See details»
Longhorn Vaccines and Diagnostics - Craft
See insights on Longhorn Vaccines and Diagnostics including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
Latest News - Diagnostics World News
Jul 31, 2024 · Vaccine development advances with IND-enabling studies underway for universal influenza vaccine LHNVD-110 ahead of Phase 1 clinical trial planned for first quarter 2025. …See details»
Longhorn Vaccines and Diagnostics Presents New Data on its
Apr 27, 2024 · LHNVD-105, a universal influenza vaccine, shows strong immunogenicity at low doses in pigs, validating previous studies in rodents; Monoclonal antibodies generated by …See details»
Longhorn’s Universal Influenza Vaccine Candidate LHNVD-105 …
Jul 20, 2021 · The addition of ALFQ to LHNVD-105 greatly increased its potency and strong antibody responses were seen using both conjugated and unconjugated formulations with …See details»
Longhorn Vaccines and Diagnostics Provides Mid-Year
Jul 31, 2024 · Vaccine development advances with IND-enabling studies underway for universal influenza vaccine LHNVD-110 ahead of Phase 1 clinical trial planned for first quarter 2025. …See details»
Longhorn Vaccines and Diagnostics to Present Data on LHNVD …
Apr 11, 2024 · The first two abstracts will detail data on LHNVD-105, an adjuvanted composite peptide universal influenza vaccine, and the monoclonal antibodies it produces.See details»
Longhorn Vaccines and Diagnostics to Present Data on ... - BioSpace
Nov 7, 2024 · LHNVD-303 is a vaccine designed to prevent antibiotic resistant bacterial infections, and clear associated toxins, including those related to Mycobacterium tuberculosis, using a …See details»
Longhorn Vaccines and Diagnostics Collaborates with Institute of ...
Sep 30, 2024 · Bethesda, MD and Gaithersburg, MD, September 30, 2024 – Longhorn Vaccines and Diagnostics, a One Health company developing vaccines and diagnostic tools for global …See details»
Longhorn Vaccines and Diagnostics sheds light on universal …
Apr 30, 2024 · The first of two studies on LHNVD-105, Longhorn’s universal influenza vaccine, showcased how unconjugated multi-epitope peptides, formulated with AddaVaxTM adjuvant, …See details»
Longhorn Vaccines and Diagnostics to Present Data on …
Nov 7, 2024 · LHNVD-303 is a vaccine designed to prevent antibiotic resistant bacterial infections, and clear associated toxins, including those related to Mycobacterium tuberculosis, using a …See details»
Longhorn Vaccines and Diagnostics Composite Peptide Vaccine …
Nov 13, 2024 · Longhorn Vaccines and Diagnostics, a One Health company developing vaccines and diagnostic tools for global public health and zoonosis concerns, presented new data at the …See details»
News - Longhorn Vaccines & Diagnostics
Apr 2, 2024 · The latest updates on Longhorn. Company-related news articles about Longhorn Vaccines & Diagnostics, PrimeStore® MTM and other related products.See details»
LHNVD 105 - AdisInsight - Springer
If your organization has a subscription, there are several access options, even while working remotely: Working within your organization’s network Login with username/password or try to …See details»
Composite Peptide Vaccines - Longhorn Vaccines & Diagnostics
LHNVD-105 is adjuvanted, universal (broadly reactive) influenza vaccine, built on a composite peptide platform. Our Patented Composite Peptide Technology allows conserved antigens …See details»